scholarly journals Cytological analysis of small branch-duct intraductal papillary mucinous neoplasms provides a more accurate risk assessment of malignancy than symptoms

CytoJournal ◽  
2011 ◽  
Vol 8 ◽  
pp. 21 ◽  
Author(s):  
Jill Ono ◽  
Kurt A. Yaeger ◽  
Muriel Genevay ◽  
Mari Mino-Kenudson ◽  
William R. Brugge ◽  
...  
Keyword(s):  
Predictive Value ◽  
High Threshold ◽  
Imaging Features ◽  
High Grade ◽  
Positive Cytology ◽  
Intraductal Papillary Mucinous Neoplasms ◽  
Branch Duct ◽  
Small Branch ◽  
Mucinous Neoplasms ◽  
Sensitivity Specificity

Objectives: The Sendai guidelines for management of patients with clinically suspected intraductal papillary mucinous neoplasms (IPMN) recommend resection of cysts > 30 mm, a dilated main pancreatic duct (MPD) > 6 mm, a mural nodule (MN), symptoms or positive cytology. Although sensitive, asymptomatic cysts, nonspecific symptoms, and a high threshold for positive cytology limit the specificity of the guidelines. We have assessed the value of cytology relative to symptom for predicting malignancy in IPMNs without high-risk imaging features. Materials and Methods: We retrospectively reviewed the clinical, radiological, and cytological data of 31 small branch-duct IPMNs without a MN. The cytological presence of high-grade atypical epithelial cells (HGA) was considered true positive, with a corresponding histology of high-grade dysplasia or invasive carcinoma. The performance of cytology versus symptoms was evaluated by calculating the sensitivity, specificity, negative predictive value (NPV), positive predictive value (PPV), and accuracy. Results: The sensitivity (0.80), specificity (0.85), and accuracy (0.84) of HGA were higher than the corresponding performance characteristics of symptoms (0.60, 0.45, and 0.48, respectively). The NPV of no HGA on cytology was > 95%. Conclusions: Cytology is a better predictor of malignancy than symptoms, for the conservative management of small branch-duct IPMNs. Cytology contributes to a highly accurate triple negative test for malignancy in small IPMN: No dilated MPD, MN or HGA.

scholarly journals The Utilization of Imaging Features in the Management of Intraductal Papillary Mucinous Neoplasms

2014 ◽  
Vol 2014 ◽  
pp. 1-9 ◽  
Author(s):  
Stefano Palmucci ◽  
Claudia Trombatore ◽  
Pietro Valerio Foti ◽  
Letizia Antonella Mauro ◽  
Pietro Milone ◽  
...  
Keyword(s):  
Pancreatic Cysts ◽  
Low Grade ◽  
Imaging Features ◽  
Main Duct ◽  
Intraductal Papillary Mucinous Neoplasms ◽  
Branch Duct ◽  
Cystic Neoplasms ◽  
Radiological Features ◽  
Increased Risk ◽  
Mucinous Neoplasms

Intraductal papillary mucinous neoplasms (IPMNs) represent a group of cystic pancreatic neoplasms with large range of clinical behaviours, ranging from low-grade dysplasia or borderline lesions to invasive carcinomas. They can be grouped into lesions originating from the main pancreatic duct, main duct IPMNs (MD-IPMNs), and lesions which arise from secondary branches of parenchyma, denominated branch-duct IPMNs (BD-IPMNs). Management of these cystic lesions is essentially based on clinical and radiological features. The latter have been very well described in the last fifteen years, with many studies published in literature showing the main radiological features of IPMNs. Currently, the goal of imaging modalities is to identify “high-risk stigmata” or “worrisome feature” in the evaluation of pancreatic cysts. Marked dilatation of the main duct (>1 cm), large size (3–5 cm), and intramural nodules have been associated with increased risk of degeneration. BD-IPMNs could be observed as microcystic or macrocystic in appearance, with or without communication with main duct. Their imaging features are frequently overlapped with cystic neoplasms. The risk of progression for secondary IPMNs is lower, and subsequently an imaging based follow-up is very often proposed for these lesions.

scholarly journals The CT fish mouth ampulla sign: a highly specific finding in main duct and mixed intraductal papillary mucinous neoplasms

2019 ◽  
Vol 92 (1103) ◽  
pp. 20190461
Author(s):  
Ting Ting Zhang ◽  
Timothy J Sadler ◽  
Siobhan Whitley ◽  
Rebecca Brais ◽  
Edmund Godfrey
Keyword(s):  
Pancreatic Duct ◽  
Predictive Value ◽  
High Grade Dysplasia ◽  
High Grade ◽  
Main Duct ◽  
Intraductal Papillary Mucinous Neoplasms ◽  
Control Series ◽  
Duct Dilatation ◽  
Mucinous Neoplasms ◽  
Pancreatic Duct Dilatation

Objective: Main duct and mixed intraductal papillary mucinous neoplasms (IPMN) are pre-malignant cystic pancreatic neoplasms associated with pancreatic duct dilatation. Distinguishing these from benign causes of pancreatic duct dilatation is important in order to allow appropriate surveillance or surgery. A patulous duodenal papilla with extrusion of mucus at endoscopic evaluation, the endoscopic fish mouth ampulla (E-FMA) sign, is reported in main duct and mixed IPMN. We aimed to establish whether a CT correlate (CT-FMA) of this sign exists and whether this was associated with the presence of invasion or high-grade dysplasia. We defined the CT-FMA sign as an uninterrupted column of water attenuation material running from the pancreatic duct to the duodenal lumen. Methods: A retrospective, blinded review of 44 patients with histologically confirmed IPMN and 87 age-matched controls with pancreatic duct dilatation on CT was undertaken. A case–control series matched for the degree of pancreatic duct dilatation was used to compare the rates of invasion or high-grade dysplasia between main duct and mixed IPMN patients, with and without a CT-FMA sign. Results: The CT-FMA sign could be identified in 18.5% patients with main duct/mixed IPMN with specificity 100%, positive predictive value 100% and negative predictive value 79.8%. A significant association was found between CT-FMA in main duct/mixed IPMN compared to controls, but not with the presence of high-grade dysplasia or invasion. Conclusions: The CT-FMA sign is a newly reported, highly specific sign of MD and mixed IPMN. Advances in knowledge: If a fish mouth ampulla is identified at CT, a diagnosis of main duct or mixed IPMN is highly likely.

Βλεννοπαραγωγά κυστικά νεοπλάσματα παγκρέατος

2020 ◽  
Author(s):  
Χαριτίνη Σάλλα
Keyword(s):  
Needle Aspiration ◽  
High Grade ◽  
Main Duct ◽  
Ultrasound Guided ◽  
Intraductal Papillary Mucinous Neoplasms ◽  
Branch Duct ◽  
Cystic Neoplasms ◽  
Fine Needle ◽  
Mucinous Cystic Neoplasms ◽  
Mucinous Neoplasms

ΣΚΟΠΟΣ: Η παρούσα διδακτορική διατριβή στοχεύει στην αξιολόγηση των κλινικών, απεικονιστικών και κυτταρολογικών κριτηρίων για την ταυτοποίηση της υψηλόβαθμης δυσπλασίας (high grade dysplasia) / καρκινώματος (HGD/Ca) στα παγκρεατικά βλεννοπαραγωγά κυστικά νεοπλάσματα (ενδοπορικά θηλώδη βλεννώδη νεοπλάσματα, intraductal papillary mucinous neoplasms, IPMNs και βλεννώδη κυστικά νεοπλάσματα, mucinous cystic neoplasms, MCNs). ΥΛΙΚΟ ΚΑΙ ΜΕΘΟΔΟΣ: Συμπεριελήφθησαν 68 διαδοχικά ιστολογικά επιβεβαιωμένα βλεννοπαραγωγά κυστικά νεοπλάσματα που διαγνώστηκαν με αναρρόφηση δια λεπτής βελόνης υπό την κατεύθυνση του ενδοσκοπικού υπερήχου (endoscopic ultrasound-guided fine needle aspiration, EUS-FNA), ειδικότερα 39 ΙPMNs παραπλεύρων κλάδων (branch duct, BD-IPMNs), 21 ΙPMNs του μείζονος παγκρεατικού πόρου (main duct, MD-IPMNs) και 8 MCNs. Οι συσχετίσεις της HGD/Ca στο εγχειρητικό υλικό με τα ευρήματα του EUS και της κυτταρολογίας, τα δημογραφικά χαρακτηριστικά, τις συνήθειες ζωής και τις κλινικές παραμέτρους αξιολογήθηκαν χωριστά για τα IPMNs και τα MCNs. ΑΠΟΤΕΛΕΣΜΑΤΑ: Ηλικία μεγαλύτερη ή ίση των 25 ετών συσχετιζόταν με HGD/Ca. Στα BD-IPMNs, η διάμετρος κύστεως μεγαλύτερη ή ίση των 3 cm (ευαισθησία 68,8%, ειδικότητα 65,2%), η παρουσία τοιχωματικού όζου (ευαισθησία 56,3%, ειδικότητα 78,3%), η διάμετρος του μείζονος παγκρεατικού πόρου 5-9 mm (ευαισθησία 50,0%, ειδικότητα 87,0%) και τα ύποπτα για κακοήθεια κυτταρολογικά ευρήματα (ευαισθησία 81,3%, ειδικότητα 100,0%) ήταν ενδεικτικά παρουσίας HGD/Ca. Ομοίως, στα MD-IPMNs, τα ύποπτα για κακοήθεια κυτταρολογικά ευρήματα ήταν ενδεικτικά HGD/Ca με υψηλή ευαισθησία (88,9%) και εξαιρετική ειδικότητα (100,0%). Όσον αφορά στα κυτταρολογικά κριτήρια, στα BD-IPMNs, η HGD/Ca συσχετιζόταν με υψηλή πυρηνοκυτταροπλασματική αναλογία, νέκρωση του υποστρώματος, παρουσία θηλωδών αθροίσεων, υπο- ή υπερχρωματικών πυρήνων και μείζονες ανωμαλίες της πυρηνικής μεμβράνης (πάχυνση ή/και οδοντώσεις). ΣΥΜΠΕΡΑΣΜΑΤΑ: Τα κλινικά, απεικονιστικά και κυτταρολογικά κριτήρια είναι χρήσιμα στην ταυτοποίηση της HGD/Ca στα IPMNs.

Imaging Features to Distinguish Malignant and Benign Branch-Duct Type Intraductal Papillary Mucinous Neoplasms of the Pancreas

2014 ◽  
Vol 259 (1) ◽  
pp. 72-81 ◽  
Author(s):  
Kyung Won Kim ◽  
Seong Ho Park ◽  
Junhee Pyo ◽  
Soon Ho Yoon ◽  
Jae Ho Byun ◽  
...  
Keyword(s):  
Imaging Features ◽  
Intraductal Papillary Mucinous Neoplasms ◽  
Branch Duct ◽  
Mucinous Neoplasms ◽  
Branch Duct Type

Cytological and Cyst Fluid Analysis of Small (≤3 cm) Branch Duct Intraductal Papillary Mucinous Neoplasms Adds Value to Patient Management Decisions

Pancreatology ◽  
2008 ◽  
Vol 8 (3) ◽  
pp. 277-284 ◽  
Author(s):  
Martha Bishop Pitman ◽  
Paul J. Michaels ◽  
Vikram Deshpande ◽  
William R. Brugge ◽  
Brenna C. Bounds
Keyword(s):  
Patient Management ◽  
Cyst Fluid ◽  
Management Decisions ◽  
Intraductal Papillary Mucinous Neoplasms ◽  
Branch Duct ◽  
Fluid Analysis ◽  
Mucinous Neoplasms

scholarly journals Radiomic nomogram based on MRI to predict grade of branching type intraductal papillary mucinous neoplasms of the pancreas: a multicenter study

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Sijia Cui ◽  
Tianyu Tang ◽  
Qiuming Su ◽  
Yajie Wang ◽  
Zhenyu Shu ◽  
...  
Keyword(s):  
Calibration Curve ◽  
Main Pancreatic Duct ◽  
Validation Cohort ◽  
External Validation ◽  
High Grade ◽  
Intraductal Papillary Mucinous Neoplasms ◽  
Training Cohort ◽  
Independent Validation ◽  
Medical Centers ◽  
Mucinous Neoplasms

Abstract Background Accurate diagnosis of high-grade branching type intraductal papillary mucinous neoplasms (BD-IPMNs) is challenging in clinical setting. We aimed to construct and validate a nomogram combining clinical characteristics and radiomic features for the preoperative prediction of low and high-grade in BD-IPMNs. Methods Two hundred and two patients from three medical centers were enrolled. The high-grade BD-IPMN group comprised patients with high-grade dysplasia and invasive carcinoma in BD-IPMN (n = 50). The training cohort comprised patients from the first medical center (n = 103), and the external independent validation cohorts comprised patients from the second and third medical centers (n = 48 and 51). Within 3 months prior to surgery, all patients were subjected to magnetic resonance examination. The volume of interest was delineated on T1-weighted (T1-w) imaging, T2-weighted (T2-w) imaging, and contrast-enhanced T1-weighted (CET1-w) imaging, respectively, on each tumor slice. Quantitative image features were extracted using MITK software (G.E.). The Mann-Whitney U test or independent-sample t-test, and LASSO regression, were applied for data dimension reduction, after which a radiomic signature was constructed for grade assessment. Based on the training cohort, we developed a combined nomogram model incorporating clinical variables and the radiomic signature. Decision curve analysis (DCA), a receiver operating characteristic curve (ROC), a calibration curve, and the area under the ROC curve (AUC) were used to evaluate the utility of the constructed model based on the external independent validation cohorts. Results To predict tumor grade, we developed a nine-feature-combined radiomic signature. For the radiomic signature, the AUC values of high-grade disease were 0.836 in the training cohort, 0.811 in external validation cohort 1, and 0.822 in external validation cohort 2. The CA19–9 level and main pancreatic duct size were identified as independent parameters of high-grade of BD-IPMNs using multivariate logistic regression analysis. The CA19–9 level and main pancreatic duct size were then used to construct the radiomic nomogram. Using the radiomic nomogram, the high-grade disease-associated AUC values were 0.903 (training cohort), 0.884 (external validation cohort 1), and 0.876 (external validation cohort 2). The clinical utility of the developed nomogram was verified using the calibration curve and DCA. Conclusions The developed radiomic nomogram model could effectively distinguish high-grade patients with BD-IPMNs preoperatively. This preoperative identification might improve treatment methods and promote personalized therapy in patients with BD-IPMNs.

Sign in / Sign up

Export Citation Format

Share Document